Comparative receptor binding analyses of cannabinoid agonists and antagonists.
about
5-HT1A receptors are involved in the cannabidiol-induced attenuation of behavioural and cardiovascular responses to acute restraint stress in ratsAntidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptorsAnalogs of JHU75528, a PET ligand for imaging of cerebral cannabinoid receptors (CB1): development of ligands with optimized lipophilicity and binding affinityCannabinoids and Epilepsy.What we know and do not know about the cannabinoid receptor 2 (CB2)The CB2 receptor and its role as a regulator of inflammationCannabidiol as a Potential New Type of an Antipsychotic. A Critical Review of the EvidenceCharacterization of palmitoylethanolamide transport in mouse Neuro-2a neuroblastoma and rat RBL-2H3 basophilic leukaemia cells: comparison with anandamideEndocannabinoid system and psychiatry: in search of a neurobiological basis for detrimental and potential therapeutic effects.The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptorsEffects of the fatty acid amide hydrolase inhibitor URB597 on pain-stimulated and pain-depressed behavior in rats.Cannabinoids Delta(9)-tetrahydrocannabinol and cannabidiol differentially inhibit the lipopolysaccharide-activated NF-kappaB and interferon-beta/STAT proinflammatory pathways in BV-2 microglial cellsThe cannabinoid agonist HU-210: pseudo-irreversible discriminative stimulus effects in rhesus monkeys.Interactions of Cannabinoids With Biochemical SubstratesThe incentive salience of alcohol: translating the effects of genetic variant in CNR1.Cannabinoid agonists and antagonists discriminated by receptor binding in rat cerebellum.3-Substituted pyrazole analogs of the cannabinoid type 1 (CB₁) receptor antagonist rimonabant: cannabinoid agonist-like effects in mice via non-CB₁, non-CB₂ mechanism.Cannabinoid receptor agonists upregulate and enhance serotonin 2A (5-HT(2A)) receptor activity via ERK1/2 signaling.Ligand Binding Sensitivity of the Extracellular Loop Two of the Cannabinoid Receptor 1.Kappa opioid mediation of cannabinoid effects of the potent hallucinogen, salvinorin A, in rodentsCannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy.Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro.Cannabidiol protects against hepatic ischemia/reperfusion injury by attenuating inflammatory signaling and response, oxidative/nitrative stress, and cell death.Heteromerization of GPR55 and cannabinoid CB2 receptors modulates signallingCannabinoid CB1 receptor-mediated modulation of evoked dopamine release and of adenylyl cyclase activity in the human neocortex.CB1 cannabinoid receptor-mediated modulation of food intake in mice.The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritisCannabidiol attenuates high glucose-induced endothelial cell inflammatory response and barrier disruption.Novel 3-substituted rimonabant analogues lack Δ(9) -tetrahydrocannabinol-like abuse-related behavioural effects in mice.Identification of novel endogenous cytochrome p450 arachidonate metabolites with high affinity for cannabinoid receptors.Meta-analysis of cannabinoid ligand binding affinity and receptor distribution: interspecies differences.G-protein receptor kinase 5 regulates the cannabinoid receptor 2-induced up-regulation of serotonin 2A receptors.Cannabinoid-related agents in the treatment of anxiety disorders: current knowledge and future perspectives.Pathways and gene networks mediating the regulatory effects of cannabidiol, a nonpsychoactive cannabinoid, in autoimmune T cells.Synthesis and CB1 cannabinoid receptor affinity of 4-alkoxycarbonyl-1,5-diaryl-1,2,3-triazolesCannabinoid-induced enhanced interaction and protein levels of serotonin 5-HT(2A) and dopamine D₂ receptors in rat prefrontal cortex.Cannabidiol attenuates cisplatin-induced nephrotoxicity by decreasing oxidative/nitrosative stress, inflammation, and cell deathCannabinoids in disguise: Δ9-tetrahydrocannabinol-like effects of tetramethylcyclopropyl ketone indoles.The emerging role of the endocannabinoid system in cardiovascular disease.In vivo Evidence for Therapeutic Properties of Cannabidiol (CBD) for Alzheimer's Disease.
P2860
Q24644922-A5D8D440-1FE9-4BD8-BF72-BCBB74F54D61Q24646841-ED730741-D064-4652-93B1-ACCFD7B3E5ABQ24650317-79875E2F-1248-480B-951D-202436C0CE3DQ27336451-C30FBB7D-8109-4A05-B2C2-C5949C1E51EDQ27686851-438D4EAA-54CD-4683-97BE-7571F3EB5356Q28066700-7EBE5E27-EA08-42B0-A160-45EFD5D3D1ABQ28075499-4FE23BDA-538F-4CDD-B4C1-98070CEDDDABQ28363051-C530E0C5-DD0F-4E29-B2BC-015C0B1E0B24Q30473707-22DC792B-0060-4BAF-A747-3B635C4BDF6EQ30486707-E1CFA4B9-DB4D-44DC-BADB-9438922C91BFQ30574567-B2D491F0-0E89-47D3-9E11-CAB7406D21C1Q33581824-E878077C-BD8C-4238-A37C-16E201CC6002Q33698310-C8BD4B7C-4394-48D4-A252-B8B9E2703B61Q33758351-40B9862A-5E01-4E47-80AE-1F0A1F9579F7Q33797978-DB15A745-A8F2-434C-B94D-3A255C873790Q33876516-91820187-8D55-4C4E-B054-950A2F7B7000Q34232856-59A136BF-A8FC-4F1D-9644-25AE415C3974Q34311721-2C034D74-86AD-4656-AAC0-B099C52C1AB3Q34412157-33718AA9-A51C-445B-BB83-C8B915E5D3C3Q34453709-74458E10-C618-4CB6-B4CF-4EF80ABCA5AAQ34519365-F15CCEFA-E14D-4F4A-8939-C4B4DB3ABB9FQ34574285-999DFB3F-1591-4C7A-983C-890891B84C79Q34851941-5C470BA4-918C-4F8F-B276-9698FE5579B8Q34953430-5F584E50-8BAA-4D93-9CD0-82DF5B08C72FQ35047001-F290B4CF-4B9C-49F9-AFA2-C4A1368F9358Q35048878-FB03E8EE-B39B-4FDD-B2DA-EACC76847340Q35208754-BFE4BF3F-3CC2-486B-A27F-04C7A1FB6A21Q36431803-1E5F55AA-6E36-4D90-9FFC-A8D704F9D9A4Q36783972-50B71C48-A4C7-41D0-B94F-40DCBFCD152BQ36861457-0F370A07-C3B3-4788-87A3-46EFE6F94262Q36887138-9099AA60-6692-4FE2-8201-D1CBEF62A060Q36890617-6A80188E-2983-49D6-A6D2-865435260A11Q36953261-376FE661-31C8-4264-BDD5-41E488D15968Q36965753-60E391C7-FE9C-4930-B665-EEE36B0D2100Q37074591-4C414352-9571-45A2-903B-7BEA141BCC47Q37104197-785EC7D4-C81C-4B96-8365-30C407C522E6Q37192723-5CF52DA2-CEE4-4A35-99A5-A37447608297Q37397048-327E135D-6298-4AA7-97F8-422605933158Q37439386-8975C81E-7B37-44EE-94D0-234A0630749BQ37622090-2B66149C-5886-4B24-A580-EDC77C2E3A5D
P2860
Comparative receptor binding analyses of cannabinoid agonists and antagonists.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
Comparative receptor binding analyses of cannabinoid agonists and antagonists.
@en
Comparative receptor binding analyses of cannabinoid agonists and antagonists.
@nl
type
label
Comparative receptor binding analyses of cannabinoid agonists and antagonists.
@en
Comparative receptor binding analyses of cannabinoid agonists and antagonists.
@nl
prefLabel
Comparative receptor binding analyses of cannabinoid agonists and antagonists.
@en
Comparative receptor binding analyses of cannabinoid agonists and antagonists.
@nl
P2093
P921
P1476
Comparative receptor binding analyses of cannabinoid agonists and antagonists
@en
P2093
A F Gilliam
B F Thomas
H H Seltzman
P304
P407
P577
1998-04-01T00:00:00Z